These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

318 related items for PubMed ID: 28159824

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Platelet-targeted thrombolysis for treatment of acute ischemic stroke.
    Palazzolo JS, Ale A, Ho H, Jagdale S, Broughton BRS, Medcalf RL, Wright DK, Alt K, Hagemeyer CE, Niego B.
    Blood Adv; 2023 Feb 28; 7(4):561-574. PubMed ID: 35482909
    [Abstract] [Full Text] [Related]

  • 4. Targeting ligand-induced binding sites on GPIIb/IIIa via single-chain antibody allows effective anticoagulation without bleeding time prolongation.
    Stoll P, Bassler N, Hagemeyer CE, Eisenhardt SU, Chen YC, Schmidt R, Schwarz M, Ahrens I, Katagiri Y, Pannen B, Bode C, Peter K.
    Arterioscler Thromb Vasc Biol; 2007 May 28; 27(5):1206-12. PubMed ID: 17322097
    [Abstract] [Full Text] [Related]

  • 5. In-vitro efficacy of different platelet glycoprotein IIb/IIIa antagonists and thrombolytics on platelet/fibrin-mediated clot dynamics in human whole blood using thrombelastography.
    Mousa SA.
    Blood Coagul Fibrinolysis; 2007 Jan 28; 18(1):55-60. PubMed ID: 17179828
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. P-selectin-targeting of the fibrin selective thrombolytic Desmodus rotundus salivary plasminogen activator alpha1.
    Dong N, Da Cunha V, Citkowicz A, Wu F, Vincelette J, Larsen B, Wang YX, Ruan C, Dole WP, Morser J, Wu Q, Pan J.
    Thromb Haemost; 2004 Nov 28; 92(5):956-65. PubMed ID: 15543321
    [Abstract] [Full Text] [Related]

  • 8. Delayed targeting of CD39 to activated platelet GPIIb/IIIa via a single-chain antibody: breaking the link between antithrombotic potency and bleeding?
    Hohmann JD, Wang X, Krajewski S, Selan C, Haller CA, Straub A, Chaikof EL, Nandurkar HH, Hagemeyer CE, Peter K.
    Blood; 2013 Apr 18; 121(16):3067-75. PubMed ID: 23380744
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. [Effects of thrombolysis on platelets and coagulation].
    Helft G, Abdelouahed M, Vacheron A, Lecompte T, Samama MM.
    Ann Cardiol Angeiol (Paris); 1995 Sep 18; 44(7):354-60. PubMed ID: 8561440
    [Abstract] [Full Text] [Related]

  • 11. Thrombus-targeted nanocarrier attenuates bleeding complications associated with conventional thrombolytic therapy.
    Absar S, Nahar K, Kwon YM, Ahsan F.
    Pharm Res; 2013 Jun 18; 30(6):1663-76. PubMed ID: 23468049
    [Abstract] [Full Text] [Related]

  • 12. Combination of a direct thrombin inhibitor and a platelet glycoprotein IIb/IIIa blocking peptide facilitates and maintains reperfusion of platelet-rich thrombus with alteplase.
    Sabatine MS, Tu TM, Jang IK.
    J Thromb Thrombolysis; 2000 Oct 18; 10(2):189-96. PubMed ID: 11005941
    [Abstract] [Full Text] [Related]

  • 13. Combination of platelet fibrinogen receptor antagonist and direct thrombin inhibitor at low doses markedly improves thrombolysis.
    Nicolini FA, Lee P, Rios G, Kottke-Marchant K, Topol EJ.
    Circulation; 1994 Apr 18; 89(4):1802-9. PubMed ID: 8149546
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Using a peptide inhibitor of the glycoprotein IIb/IIIa platelet receptor: initial experience in patients with acute peripheral arterial occlusions.
    Yoon HC, Miller FJ.
    AJR Am J Roentgenol; 2002 Mar 18; 178(3):617-22. PubMed ID: 11856686
    [Abstract] [Full Text] [Related]

  • 16. Incomplete inhibition of platelet aggregation and glycoprotein IIb-IIIa receptor blockade by abciximab: importance of internal pool of glycoprotein IIb-IIIa receptors.
    Gawaz M, Ruf A, Pogatsa-Murray G, Dickfeld T, Rüdiger S, Taubitz W, Fischer J, Müller I, Meier D, Patscheke H, Schömig A.
    Thromb Haemost; 2000 Jun 18; 83(6):915-22. PubMed ID: 10896249
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Inhibition of microsurgical thrombosis by the platelet glycoprotein IIb/IIIa antagonist SR121566A.
    Ching S, Thoma A, Monkman S, Kelton JG.
    Plast Reconstr Surg; 2003 Jul 18; 112(1):177-85. PubMed ID: 12832891
    [Abstract] [Full Text] [Related]

  • 19. Effect of glycoprotein IIb/IIIa inhibitors on CD62p expression, platelet aggregates, and microparticles in vitro.
    Matzdorff AC, Kühnel G, Kemkes-Matthes B, Pralle H, Voss R, Fareed J.
    J Lab Clin Med; 2000 Mar 18; 135(3):247-55. PubMed ID: 10711863
    [Abstract] [Full Text] [Related]

  • 20. Short- and long-term results of abciximab versus aspirin in conjunction with thrombolysis for patients with peripheral occlusive arterial disease and arterial thrombosis.
    Schweizer J, Kirch W, Koch R, Müller A, Hellner G, Forkmann L.
    Angiology; 2000 Nov 18; 51(11):913-23. PubMed ID: 11103860
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.